Home
»
Press Room
»
Genome Editing Market To Reach $25.00 Billion By 2030

Genome Editing Market To Reach $25.00 Billion By 2030

April 2025 | Report Format: Electronic (PDF)

Genome Editing Market Growth & Trends

The global genome editing market size is expected to reach USD 25.00 billion in 2030 and is projected to grow at a CAGR of 16.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth.

The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.

The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.

key Request a free sample copy or view report summary: Genome Editing Market Report

Genome Editing Market Report Highlights

Gene editing technology CRISPR is projected to be the burgeoning technology in biotechnology. CRISPR harnesses the bacterial immune system to either knock genes out or insert new genes.
The rapid advancement of genome editing technologies is reshaping the therapeutic landscape, driving a surge in clinical trials aimed at treating a wide range of genetic, hematologic, metabolic, and infectious diseases.
In vivo genome editing is emerging as a transformative force within the global therapeutic landscape. Unlike traditional ex vivo methods, in vivo approaches allow for direct gene modification inside the patient’s body, eliminating the need for complex cell extraction, manipulation, and reinfusion.
The CRISPR/Cas9 segment held the largest market share of 44.36% of the global revenue in 2024. This can be attributed to high precision & efficiency, high versatility & adaptability to different experimental designs, and cost-effectiveness with relatively low expense associated
North America genome editing market dominated the global market and accounted for a 44.59% share in 2024, owing to the growing investments in the R&D of gene editing technologies.

Genome Editing Market Segmentation

Grand View Research has segmented the global genome editing market report based on technology, method, application, mode, end use, and region:

Genome Editing Technology Outlook (Revenue, USD Million, 2018 - 2030)

(CRISPR)/Cas9
TALENs/MegaTALs
ZFN
Meganucleases
Others

Genome Editing Delivery Method Outlook (Revenue, USD Million, 2018 - 2030)

Ex-vivo
In-vivo

Genome Editing Application Outlook (Revenue, USD Million, 2018 - 2030)

Genetic Engineering
- Cell line engineering
- Animal genetic engineering
- Plant genetic engineering
- Others
Clinical Applications
- Diagnostics Development
- Therapy Development